Empagliflozin + linagliptin

Trade Name: 
Glyxambi
Manufacturer/Distributor: 
Boehringer Ingelheim Canada
Classification: 
Antidiabetic agent
DPPT-4 inhibitor + SGLT2 inhibitor
ATC Class: 
A10BD19 - combination of oral blood glucose lowering drugs
Status: 
active
Notice of Compliance (yyyy/mm/dd): 
2016/12/15
Date Marketed in Canada (yyyy/mm/dd): 
2016/12/15
Presentation: 
Tablet: 10 mg empagliflozin + 5 mg linagliptin. DIN: 02459752
Tablet: 25 mg empagliflozin + 5 mg linagliptin. DIN: 02459760
Comments: 
For use in combination with metformin as an adjunct to diet and exercise, to achieve glycemic control in adult patients with type 2 diabetes mellitus who are inadequately controlled on metformin and empagliflozin, or inadequately controlled on metformin and linagliptin.